




PHARMACEUTICAL 2023

ENDONOVO THERAPEUTICS INC.
Rank 435 of 446





RealRate

PHARMACEUTICAL 2023

ENDONOVO THERAPEUTICS INC. Rank 435 of 446

The relative strengths and weaknesses of ENDONOVO THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDONOVO THERAPEUTICS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 318% points. The greatest weakness of ENDONOVO THERAPEUTICS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 260% points.

The company's Economic Capital Ratio, given in the ranking table, is -425%, being 468% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16
Cost of Goods Sold	10.0
Intangible Assets	1,265
Liabilities, Current	33,382
Liabilities, Non-Current	80
Other Assets	0
Other Compr. Net Income	0
Other Expenses	3,390
Other Liabilities	0
Other Net Income	-15,210
Other Revenues	135
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	1,281
Liabilities	33,462
Expenses	3,400
Revenues	135
Stockholders Equity	-32,180
Net Income	-18,475
Comprehensive Net Income	-18,475
Economic Capital Ratio	-425%